Based on 13 studies, the meta-analysis revealed loneliness and social isolation were associated with increased all-cause mortality (hazard ratio, 1.34; P < 0.001) and cancer-specific mortality (hazard ...

(HealthDay News) — Among survivors of drug overdose, fewer than half visited the emergency department, according to a study published online in JAMA Network Open.

(HealthDay News) — Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes ...

Unlike traditional Medicare patients, Medicare Advantage enrollees who need major genitourinary or gastrointestinal cancer surgery frequently use lower quality hospitals rather than high-quality ...

Cardiovascular, kidney, and metabolic (CKM) syndrome affects nearly 90% of adults in the US, but most people don't know it. (HealthDay News) — Most U.S. adults have not heard of ...

A substudy of the phase 1/2 KEYMAKER-U03 trial tested novel pembrolizumab-based triplet regimens for first-line treatment of advanced clear cell renal cell carcinoma (ccRCC).

Cancer deaths have increased by more than 70% globally over the last 3 decades and are estimated to continue to climb, researchers report.

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.

In the absence of head-to-head randomized trials, investigators performed a network meta-analysis to compared drugs for post-transplant diabetes.

Micro-energy treatments include low-intensity extracorporeal shockwave therapy, low-intensity pulsed ultrasound, and electromagnetic fields.

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.